Drugs / PegIFN
PegIFN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01095835 | Feb 2005 → Jan 2010 | chronic hepatitis B virus infection | Hoffmann-La Roche | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2017-10-23 | Replicor Inc. | Results Replicor discloses the persistence of functional control off-therapy in 80% of patients with chronic hepatitis B from the REP 401 study at AASLD 2017 replicor.com ↗
This functional control is persisting in all patients (80%) after removal of all therapy with data available for 24 weeks in 4 patients, 12 weeks in 3 patients and 4 weeks in 1 patient. |
| 2011-03-07 | Bristol-Myers Squibb | Results New Data on Multiple Bristol-Myers Squibb Investigational Hepatitis C Compounds to be Presented at The International Liver Congress 2011 bms.com ↗
Pegylated Interferon-Lambda (PEGIFN-λ) shows superior viral response with improved safety and tolerability versus PEGIFNα-2A in HCV patients (G1/2/3/4): EMERGE Phase IIb through week 12 (Late-Breakers Oral Session) |
| 2010-10-01 | Bristol-Myers Squibb | Results New Data on Multiple Bristol-Myers Squibb Compounds to be Presented at AASLD 2010 bms.com ↗
Combination therapy with BMS-790052 and BMS-650032 alone or with pegIFN/RBV results in undetectable HCV RNA through 12 weeks of therapy in HCV genotype 1 null responders |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-10-23 | Replicor Inc. | Replicor discloses the persistence of functional control off-therapy in 80% of patients with chronic hepatitis B from the REP 401 study at AASLD 2017 replicor.com ↗ |
| 2011-03-07 | Bristol-Myers Squibb | New Data on Multiple Bristol-Myers Squibb Investigational Hepatitis C Compounds to be Presented at The International Liver Congress 2011 bms.com ↗ |
| 2010-10-01 | Bristol-Myers Squibb | New Data on Multiple Bristol-Myers Squibb Compounds to be Presented at AASLD 2010 bms.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PegIFN | “Treatment with peginterferon α-2a (PegIFN) for 48 weeks is the standard of care for selected HBeAg-negative patients chronically infected with hepatitis B virus (HBV), but with...” PMID 22859496 ↗ Aug 20121“Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg” NCT01095835 ↗ |
| Known as | peginterferon α-2a | “Treatment with peginterferon α-2a (PegIFN) for 48 weeks is the standard of care for selected HBeAg-negative patients chronically infected with hepatitis B virus (HBV), but with...” PMID 22859496 ↗ Aug 2012 |
| Known as | Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01095835 ↗ |
| Route | Subcutaneous | “PEG-IFN alfa-2a 180 micrograms (mcg) was administered subcutaneously, once weekly from Week 0 to 48.” NCT01095835 ↗ |